SNY (Sanofi) Debt-to-Equity : 0.33 (As of Jun. 2024)

View and export this data going back to 2002. Start your Free Trial

What is Sanofi Debt-to-Equity?

Sanofi's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $10,242 Mil. Sanofi's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $15,324 Mil. Sanofi's Total Stockholders Equity for the quarter that ended in Jun. 2024 was $78,245 Mil. Sanofi's debt to equity for the quarter that ended in Jun. 2024 was 0.33.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Sanofi's Debt-to-Equity or its related term are showing as below:

SNY' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.25 Med: 0.32 Max: 0.52
Current: 0.33

During the past 13 years, the highest Debt-to-Equity Ratio of Sanofi was 0.52. The lowest was 0.25. And the median was 0.32.

SNY's Debt-to-Equity is ranked worse than
53.33% of 825 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs SNY: 0.33

Sanofi Debt-to-Equity Historical Data

The historical data trend for Sanofi's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanofi Debt-to-Equity Chart

Sanofi Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.44

0.33

0.28

0.25

Sanofi Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Debt-to-Equity	Get a 7-Day Free Trial															0.30	0.28	0.29	0.25	0.33

Competitive Comparison of Sanofi's Debt-to-Equity

For the Drug Manufacturers - General subindustry, Sanofi's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sanofi's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sanofi's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Sanofi's Debt-to-Equity falls into.

Sanofi Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Sanofi's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2529.989	+	17559.433)	/	80741.549
	=	0.25

Sanofi's Debt to Equity Ratio for the quarter that ended in Jun. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(10242.196	+	15324.004)	/	78245.425
	=	0.33

Sanofi (NAS:SNY) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Sanofi Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Sanofi's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Sanofi Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (NAS:SNY) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

SNYNF:USA SNY:Mexico 1SAN:Italy SANp:UK 0O59:UK SAN:France SNW:Germany SNW:Germany SNW:Germany SNW2:Germany SNW:Germany SNW:Bulgaria SANO:Austria

Address

46, avenue de la Great Army, Paris, FRA, 75017

Website

https://www.sanofi.com

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.